Genasense chronic leukemia NDA gets rolling
This article was originally published in Pharmaceutical Approvals Monthly
Genta has initiated a rolling NDA for use of Genasense (oblimersen) in combination with fludarabine and cyclophosphamide in fludarabine-experienced chronic lymphocytic leukemia patients, the firm says June 30. Genta expects to complete the submission within six months. The company previously indicated it would initiate a confirmatory CLL study for accelerated approval before year-end (1Pharmaceutical Approvals Monthly June 2005, p. 3); the company says it "plans to discuss the design of that study with FDA." The CLL NDA will include a Phase I/II study of Genasense alone in relapsed/refractory CLL and a Phase III study of Genasense in combination with the flu/cy regimen versus fly/cy alone. The latter study showed a significant benefit for complete response, but Genta said overall survival "is too early to analyze"...
You may also be interested in...
Genta plans to launch a confirmatory trial of Genasense (oblimersen sodium) in chronic lymphocytic leukemia (CLL) before the end of 2005, the firm says.
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.